High-dose chemotherapy and hematopoietic stem cell transplantation for patients with nasopharyngeal cancer: A feasibility study

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Nasopharyngeal cancer (NPC) is a highly chemosensitive malignancy. The purpose of this study was to evaluate the clinical efficacy of high-dose chemotherapy (HDCT) in combination with hematopoietic stem cell transplantation in patients with locally advanced or metastatic NPC. Methods: Nine patients with locally advanced or metastatic NPC were recruited after three to four courses of cisplatin-based chemotherapy followed by a single course of cyclophosphamide 1600 mg/m2 day 1-4, carboplatin 400 mg/m2 day 1-3, and thiotepa 120 mg/m2 day 1-4 or melphalan 120 mg/m2 day 5. Chemoirradiation was administered after HDCT only if the patient had never received radiotherapy or had residual cervical nodes. Results: A median of 8.32 × 106 CD34+ cells/kg was collected. Two patients were rendered disease-free before HDCT, one by massectomy and one by cisplatin-based chemotherapy. All patients recovered rapidly after peripheral blood stem cell transplantation (PBSCT). Among seven assessable patients, response to HDCT was observed in four patients. Only one patient achieved complete response after HDCT. The median time to failure and median survival after HDCT was eight and 18 months, respectively. One patient died of pulmonary hemorrhage two months after transplantation. No long-term disease-free survival was noted. Conclusion: HDCT with autologous PBSCT is feasible with an acceptable toxicity, and can convert partial remission into complete remission. While no long-term disease-free survival was observed in this study, further investigations are needed to establish the role of HDCT in the treatment of NPC.

Original languageEnglish
Pages (from-to)331-335
Number of pages5
JournalJapanese Journal of Clinical Oncology
Volume33
Issue number7
DOIs
Publication statusPublished - 2003 Jul 1

Fingerprint

Nasopharyngeal Neoplasms
Hematopoietic Stem Cell Transplantation
Feasibility Studies
Drug Therapy
Peripheral Blood Stem Cell Transplantation
Cisplatin
Disease-Free Survival
Thiotepa
Melphalan
Carboplatin
Combination Drug Therapy
Cyclophosphamide
Radiotherapy
Transplantation
Hemorrhage

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

@article{1e4a07fa569b4295a54a68f121bf2854,
title = "High-dose chemotherapy and hematopoietic stem cell transplantation for patients with nasopharyngeal cancer: A feasibility study",
abstract = "Background: Nasopharyngeal cancer (NPC) is a highly chemosensitive malignancy. The purpose of this study was to evaluate the clinical efficacy of high-dose chemotherapy (HDCT) in combination with hematopoietic stem cell transplantation in patients with locally advanced or metastatic NPC. Methods: Nine patients with locally advanced or metastatic NPC were recruited after three to four courses of cisplatin-based chemotherapy followed by a single course of cyclophosphamide 1600 mg/m2 day 1-4, carboplatin 400 mg/m2 day 1-3, and thiotepa 120 mg/m2 day 1-4 or melphalan 120 mg/m2 day 5. Chemoirradiation was administered after HDCT only if the patient had never received radiotherapy or had residual cervical nodes. Results: A median of 8.32 × 106 CD34+ cells/kg was collected. Two patients were rendered disease-free before HDCT, one by massectomy and one by cisplatin-based chemotherapy. All patients recovered rapidly after peripheral blood stem cell transplantation (PBSCT). Among seven assessable patients, response to HDCT was observed in four patients. Only one patient achieved complete response after HDCT. The median time to failure and median survival after HDCT was eight and 18 months, respectively. One patient died of pulmonary hemorrhage two months after transplantation. No long-term disease-free survival was noted. Conclusion: HDCT with autologous PBSCT is feasible with an acceptable toxicity, and can convert partial remission into complete remission. While no long-term disease-free survival was observed in this study, further investigations are needed to establish the role of HDCT in the treatment of NPC.",
author = "Chen, {Tsai Yun} and Chen, {Helen H.W.} and Su, {Wu Chou} and Tsao, {Chao Jung}",
year = "2003",
month = "7",
day = "1",
doi = "10.1093/jjco/hyg064",
language = "English",
volume = "33",
pages = "331--335",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - High-dose chemotherapy and hematopoietic stem cell transplantation for patients with nasopharyngeal cancer

T2 - A feasibility study

AU - Chen, Tsai Yun

AU - Chen, Helen H.W.

AU - Su, Wu Chou

AU - Tsao, Chao Jung

PY - 2003/7/1

Y1 - 2003/7/1

N2 - Background: Nasopharyngeal cancer (NPC) is a highly chemosensitive malignancy. The purpose of this study was to evaluate the clinical efficacy of high-dose chemotherapy (HDCT) in combination with hematopoietic stem cell transplantation in patients with locally advanced or metastatic NPC. Methods: Nine patients with locally advanced or metastatic NPC were recruited after three to four courses of cisplatin-based chemotherapy followed by a single course of cyclophosphamide 1600 mg/m2 day 1-4, carboplatin 400 mg/m2 day 1-3, and thiotepa 120 mg/m2 day 1-4 or melphalan 120 mg/m2 day 5. Chemoirradiation was administered after HDCT only if the patient had never received radiotherapy or had residual cervical nodes. Results: A median of 8.32 × 106 CD34+ cells/kg was collected. Two patients were rendered disease-free before HDCT, one by massectomy and one by cisplatin-based chemotherapy. All patients recovered rapidly after peripheral blood stem cell transplantation (PBSCT). Among seven assessable patients, response to HDCT was observed in four patients. Only one patient achieved complete response after HDCT. The median time to failure and median survival after HDCT was eight and 18 months, respectively. One patient died of pulmonary hemorrhage two months after transplantation. No long-term disease-free survival was noted. Conclusion: HDCT with autologous PBSCT is feasible with an acceptable toxicity, and can convert partial remission into complete remission. While no long-term disease-free survival was observed in this study, further investigations are needed to establish the role of HDCT in the treatment of NPC.

AB - Background: Nasopharyngeal cancer (NPC) is a highly chemosensitive malignancy. The purpose of this study was to evaluate the clinical efficacy of high-dose chemotherapy (HDCT) in combination with hematopoietic stem cell transplantation in patients with locally advanced or metastatic NPC. Methods: Nine patients with locally advanced or metastatic NPC were recruited after three to four courses of cisplatin-based chemotherapy followed by a single course of cyclophosphamide 1600 mg/m2 day 1-4, carboplatin 400 mg/m2 day 1-3, and thiotepa 120 mg/m2 day 1-4 or melphalan 120 mg/m2 day 5. Chemoirradiation was administered after HDCT only if the patient had never received radiotherapy or had residual cervical nodes. Results: A median of 8.32 × 106 CD34+ cells/kg was collected. Two patients were rendered disease-free before HDCT, one by massectomy and one by cisplatin-based chemotherapy. All patients recovered rapidly after peripheral blood stem cell transplantation (PBSCT). Among seven assessable patients, response to HDCT was observed in four patients. Only one patient achieved complete response after HDCT. The median time to failure and median survival after HDCT was eight and 18 months, respectively. One patient died of pulmonary hemorrhage two months after transplantation. No long-term disease-free survival was noted. Conclusion: HDCT with autologous PBSCT is feasible with an acceptable toxicity, and can convert partial remission into complete remission. While no long-term disease-free survival was observed in this study, further investigations are needed to establish the role of HDCT in the treatment of NPC.

UR - http://www.scopus.com/inward/record.url?scp=0141817906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141817906&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyg064

DO - 10.1093/jjco/hyg064

M3 - Article

C2 - 12949058

AN - SCOPUS:0141817906

VL - 33

SP - 331

EP - 335

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 7

ER -